Omeros Corporation (NASDAQ:OMER) shares shot up 4.6% on Thursday . The stock traded as high as $11.73 and last traded at $11.70, with a volume of 288,964 shares trading hands. The stock had previously closed at $11.19.

Several brokerages have weighed in on OMER. Maxim Group reiterated a “buy” rating and issued a $30.00 target price on shares of Omeros Corporation in a research note on Thursday. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. FBR & Co reiterated an “outperform” rating and issued a $38.00 target price on shares of Omeros Corporation in a research note on Wednesday, June 29th. WBB Securities reiterated a “buy” rating and issued a $75.00 target price on shares of Omeros Corporation in a research note on Tuesday, June 14th. Finally, Cantor Fitzgerald began coverage on Omeros Corporation in a research note on Thursday, June 2nd. They issued a “buy” rating and a $21.00 target price on the stock. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $38.22.

The stock has a 50-day moving average of $11.06 and a 200 day moving average of $12.09. The stock’s market capitalization is $460.23 million.

Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.11. The business earned $7.40 million during the quarter, compared to analysts’ expectations of $8.79 million. During the same quarter in the prior year, the firm earned ($0.51) EPS. The firm’s quarterly revenue was up 1797.4% compared to the same quarter last year. Equities analysts predict that Omeros Corporation will post ($1.76) EPS for the current year.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $11.42, for a total transaction of $181,578.00. Following the sale, the vice president now owns 179,497 shares in the company, valued at $2,049,855.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Other hedge funds have recently made changes to their positions in the company. Bank of Montreal Can boosted its stake in shares of Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock valued at $20,885,000 after buying an additional 454,055 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock valued at $1,827,000 after buying an additional 694 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 1,249 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in shares of Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 45,145 shares during the last quarter.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.